These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10357404)

  • 41. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
    Ajani JA; Lee FC; Singh DA; Haller DG; Lenz HJ; Benson AB; Yanagihara R; Phan AT; Yao JC; Strumberg D
    J Clin Oncol; 2006 Feb; 24(4):663-7. PubMed ID: 16446338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
    Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
    BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma.
    Spiridonidis CH; Laufman LR; Jones JJ; Gray DJ; Cho CC; Young DC
    Cancer; 1996 Nov; 78(10):2070-7. PubMed ID: 8918399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
    Uncu D; Ozdemir NY; Aksoy S; Abali H; Oksuzoglu BC; Budakoglu B; Yildiz R; Aslan N; Zengin N
    Asian Pac J Cancer Prev; 2010; 11(6):1493-7. PubMed ID: 21338186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
    Mingol F; Gallego J; Orduña A; Martinez-Blasco A; Sola-Vera J; Moya P; Morcillo MA; Ruiz JA; Calpena R; Lacueva FJ
    BMC Surg; 2015 May; 15():66. PubMed ID: 25997454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.
    Ozdemir N; Abali H; Vural M; Yalcin S; Oksuzoglu B; Civelek B; Oguz D; Bostanci B; Yalcin B; Zengin N
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1139-47. PubMed ID: 25234436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
    Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH
    Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.
    Li J; Yao X; Kortmansky JS; Fischbach NA; Stein S; Deng Y; Zhang Y; Doddamane I; Karimeddini D; Hochster HS; Lacy J
    Am J Clin Oncol; 2017 Apr; 40(2):146-151. PubMed ID: 25144267
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
    Lee KW; Im SA; Yun T; Song EK; Na Ii; Shin H; Choi IS; Oh DY; Kim JH; Kim DW; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2005 Dec; 35(12):720-6. PubMed ID: 16332718
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma.
    Raab R; Sparano JA; Ocean AJ; Christos P; Ramirez M; Vinciguerra V; Kaubisch A
    Am J Clin Oncol; 2010 Feb; 33(1):61-5. PubMed ID: 19738454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
    J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus.
    Kulke MH; Wu B; Clark JW; Enzinger PC; Lynch TJ; Vincitore M; Michelini A; Fuchs CS
    Cancer Invest; 2006; 24(3):229-34. PubMed ID: 16809148
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
    Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
    Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
    Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
    Wu Z; Ma S; Jing S; Deng Q; Zheng Z; Wu K; Li J; Chen S; Tang R; Li X
    Hepatogastroenterology; 2014 Jun; 61(132):972-7. PubMed ID: 26158151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.